Express Scripts (ESRX) Stock Price & Analysis
Score
AI Analysis
SnapshotExpress Scripts Holding is a mixed profile at 56/100 — Value 59, Growth 67, Quality 41. Under the hood: P/E 11.9, about 60% below its own multi-year median.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Express Scripts Holding Company (ESRX) last printed $92.33. Equity value is $0. Trailing earnings multiple 11.85. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| $21.98B | $24.75B | $44.97B | $46.13B | $93.86B | $104.1B | $100.89B | $101.75B | $100.29B | $100.06B |
About
Express Scripts, established in 1986, functions as a pharmacy benefit management (PBM) enterprise. It offers a comprehensive array of integrated services, including the processing of prescription claims, home delivery of medications, strategic management of drug formularies, specialized pharmaceutical support via its Accredo division, and insightful analytics derived from drug usage data. The company became a subsidiary of Cigna in December 2018, following its acquisition for $54 billion.